SUPPLEMENT

Q4 2021 — Earnings infographic

Q4 2021PDF · 1 pages3.9 MB
Joaquin Duato
Chief Executive Officer
Johnson & Johnson
“Our 2021 performance reflects continued strength
across all segments of our business. Guided by
Our Credo, I am honored to assume the role of
CEO, leading our global teams in continuing our
work to deliver life-changing solutions to consumers,
patients, and health care providers. Given our strong
results, financial profile, and innovative pipeline we
are well positioned for success in 2022 and beyond.”
For full financial data and non-GAAP reconciliations, please refer to Johnson & Johnson’s earnings release issued on January 25, 2022, available at
http://www.investor.jnj.com/sales-earnings.cfm.
*Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most
comparable GAAP financial measures.
Non-GAAP measure; excludes the impact of translational currency.
Caution Concerning Forward-Looking Statements: This document contains “forward-looking statements” as defined in the Private Securities Litigation
Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are
based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially
from the assumptions, expectations, and projections expressed in any forward-looking statements, review the “Note to Investors Concerning Forward-
Looking Statements” included in the Johnson & Johnson earnings release issued on January 25, 2022, as well as the most recently filed Johnson & Johnson
Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future
events or developments.
Full Year 2021 Results
2021 Sales
Adjusted Diluted Earnings Per Share*
$9.80 	22.0%
Increased 
Diluted Earnings Per Share
$7.81 	41.7%
Increased 
Worldwide
Increased 
$93.8B 	12.8%*
13.6%
Worldwide
Increased  	Excluding acquisitions/
divestitures on an
operational basis
Note: values may have been rounded
$27.1Medical Devices worldwide reported sales increased 17.9%
or 16.2% operationally¹. Primary operational drivers:
 
Worldwide Medical Devices Sales
Billion
Surgical Vision	Wound Closure	Electrophysiology 	Contact Lens 	Trauma
Endocutters	Energy	Biosurgery 	Hips 	Knees
Billion
$52.1 Worldwide Pharmaceutical SalesPharmaceutical worldwide reported sales increased 14.3%
or 13.1% operationally¹. Primary operational drivers:
Consumer Health worldwide reported sales increased 4.1%
or 2.8% operationally¹. Primary operational drivers:
$14.6 	Worldwide Consumer Health Sales
Billion

-- 1 of 1 --